Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily.
Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89 billion for the quarter, above the Wall Street consensus of $4.45 billion.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Gilead said its projects total product sales between $30 billion and $31 billion this year, equal to what analysts were expecting, Reuters reports.
Separately, social media chatter is circulating that said Gilead Harvoni U.S. sales ($1.707 billion) missed expectations by over 20 percent, while international sales ($1.638 billion) beat by 80 percent.
These figures have not been verified by an analyst; Gilead has not yet returned a request for comment on this issue.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.